MedTrace Logo

IVIM & OLINK in Sarcoma

NCT05950594 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-03-16

No results posted yet for this study

Summary

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Conditions

  • Soft Tissue Sarcoma

Interventions

RADIATION

Radiotherapy

Standard of care pre-operative radiotherapy

OTHER

Surgery

Standard of care definitive surgery

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950594 on ClinicalTrials.gov